<DOC>
	<DOCNO>NCT00742638</DOCNO>
	<brief_summary>This open label , randomise , parallel-group study compare efficacy safety quetiapine valproate use monotherapy treatment mania patient hospitalise acute manic episode . After give informed consent undergo screening procedure , patient randomise quetiapine valproate group Day 1 . The efficacy study treatment symptom mania assess Day 28 . Patients permit use psychoactive antipsychotic medication throughout study period expressly permit protocol . At centre , individual administer specific psychiatric assessment patient study visit order reduce variability rating scale score . Before initiation study , consistency assessment do among investigator conduct scale assessment centre .</brief_summary>
	<brief_title>To Evaluate Efficiency Safety Quetiapine Fumarate Treatment Acute Manic Patients With Bipolar Disorder .</brief_title>
	<detailed_description>The rationale use quetiapine treat patient acute mania multifold . A potential major advantage quetiapine demonstrate tolerability . Because low incidence EPS , quetiapine well tolerate antipsychotic medication sensitive patient population . The limited potential weight gain prolactin elevation may promote long-term treatment compliance . The effect quetiapine alone adjunctive mood stabilizer treatment acute mania patient bipolar disorder confirm 4 phase III clinical trial ( 8,9 ) . Based result clinical trial , use Seroquel acute mania bipolar disorder approve US , UK major market Europe . Quetiapine also recommend alternative therapy acute mania treatment practice guideline ( 10 ) . The present study ass effectiveness quetiapine valproate treatment Chinese patient acute mania treatment period 4 week . Primary objective The primary objective study evaluate effectiveness quetiapine fumarate use monotherapy treatment symptom acute mania patient bipolar disorder , evaluation change baseline YMRS total score Day 28 ( LOCF ) . Secondary objectives The secondary objective study evaluate following : - The effectiveness quetiapine use monotherapy treat symptom patient acute mania evaluation YMRS/CGI response rate Day 28 ( LOCF ) - The effectiveness quetiapine use monotherapy improve clinical status patient acute mania evaluation change baseline CGI-S score Day 28 ( LOCF ) - The effectiveness quetiapine use monotherapy treat depressive symptom patient acute mania evaluation change baseline MADRS total score Day 28 ( LOCF ) - The effectiveness quetiapine use monotherapy treat psychotic symptom patient acute mania evaluation change baseline PANSS total score Day 28 ( LOCF ) - The safety tolerability quetiapine use monotherapy treat symptom patient acute mania</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Written inform consent study participation , sign patient 's legal guardian Aged 18 65 ( inclusive ) Is hospitalize psychiatric unit acute manic episode bipolar disorder define CCMD3 criterion i.e . [ 31.2 ] bipolar disorder whose current status mania without psychotic symptom [ 31.3 ] bipolar disorder whose current status mania psychotic symptom Both screen randomization ( Day 1 ) , YMRS total score least 20 Be able understand comply requirement study , judge investigator Manic index episode judge direct physiological consequence medical condition treatment . These condition include : degenerative neurological condition ( e.g . Parkinson 's disease , Huntington 's disease ) , cerebrovascular disease ( e.g. , stroke ) , metabolic condition ( e.g. , Vitamin B12 deficiency ) , autoimmune condition ( e.g. , systemic lupus erythematosus ) , viral infection ( e.g. , hepatitis , mononucleosis , human immunodeficiency ) , certain cancer . Manic index episode judge direct physiological effect substance abuse , include intoxication withdrawal alcohol , amphetamine related substance , cocaine , sedative , hypnotic , anxiolytic ; intoxication hallucinogen , inhalant , opioids , phencyclidine related substance . Patients meet CCMD3 criterion rapid cycling : least 4 episode mood disturbance previous 12 month meet criterion hypomanic/manic nonmajor depression/depression , mixed episode Known intolerance lack response quetiapine valproate , judge investigator Known suspect hypersensitivity quetiapine valproate Known lack response clozapine Use clozapine within 28 day randomization ( Day 1 ) Women pregnancy lactation , female childbearing potential without appropriate birth control measure Substance alcohol dependence ( except nicotine dependence ) , define CCMD3 , within 1 month randomisation ( Day 1 ) . Continuous daily use benzodiazepine month precede screen . Receipt electroconvulsive therapy ( ECT ) within 30 day prior randomisation ( Day 1 ) . Use antidepressant ( ) screen period ( Day 7 Day 1 ) within period 5 halflives drug ( ) prior randomisation ( Day 1 ) . Use longacting antipsychotic medication within 30 day prior randomisation ( Day 1 ) Thyroidstimulating hormone concentration 10 % upper limit normal range , regardless treatment hypothyroidism hyperthyroidism . Use potent cytochrome P450 3A4 inhibitor 14 day precede randomization ( Day 1 ) , e.g. , ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , saquinavir . Use potent cytochrome P450 inducer ( e.g . Phenytoin , carbamazepine , barbiturate , rifampin , glucocorticoid , St. John 's Wort ) 14 day precede randomisation ( Day 1 ) . Renal , cardiovascular , hepatic , haematological , endocrine , congestive heart failure , disease clinical find unstable opinion investigator would negatively affect study medication would affect study medication . Patients diabetes mellitus ( DM ) fulfil one follow criterion : Unstable DM define enrolment HbA1c &gt; 8.5 % Admitted hospital treatment DM DM relate illness past 12 week Not care physician responsible patient 's DM care Physician responsible patient 's DM care indicate patient 's DM control Physician responsible patient 's DM care approve patient 's participation study Has dose oral hypoglycaemic drug ( ) and/or diet 4 week prior randomisation . For thiazolidinediones ( glitazones ) period le 8 week Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week Participation another clinical study within 4 week randomisation ( Day 1 ) . Lack response previous systemic treatment lithium and/or quetiapine . Medical condition would affect absorption , distribution , metabolism excretion study treatment . An absolute neutrophil count ( ANC ) &lt; 1.5 x 109/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>CCMD-3 ,</keyword>
	<keyword>CRF ,</keyword>
	<keyword>EPS ,</keyword>
	<keyword>GCP ,</keyword>
	<keyword>ICH ,</keyword>
	<keyword>ITT ,</keyword>
	<keyword>LOCF ,</keyword>
	<keyword>MADRS ,</keyword>
	<keyword>PANSS ,</keyword>
	<keyword>YMRS .</keyword>
	<keyword>Acute</keyword>
	<keyword>manic</keyword>
	<keyword>patient</keyword>
	<keyword />
	<keyword>bipolar</keyword>
	<keyword>disorder</keyword>
</DOC>